OCSAW — Oculis Holding AG
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953530 ·
Last close
$2.74
Market Cap
—
52W High
$2.93
52W Low
$2.68
ADV30
3,730
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -23,568,000 | -9,970,000 | 250,335,000 | 61,614,000 | 30,998,000 |
| Mar 2026 | 0 | — | -21,728,000 | -28,852,000 | 243,993,000 | 64,564,000 | 47,345,000 |
| Dec 2025 | 0 | — | -20,633,000 | -23,514,000 | 235,963,000 | 81,329,000 | 39,893,000 |
| Sep 2025 | 0 | — | -20,296,000 | -16,855,000 | 167,836,000 | 46,440,000 | 37,242,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,678,000
Investing CF
$-34,945,000
Financing CF
$106,690,000
CapEx
$-295,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-413,366,000
Inventory
—
Receivables
$1,576,000
ST Investments
$157,470,000
EBIT TTM
$-94,128,000
Pretax Income TTM
$-94,887,000
Interest Exp TTM
$759,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,672,000 | -98,957,000 | 235,963,000 | 39,893,000 | 196,070,000 | -66,304,000 |
| Dec 2024 | 0 | -73,204,000 | -85,777,000 | 120,353,000 | 46,970,000 | 73,383,000 | -48,919,000 |
| Dec 2023 | 0 | -45,851,000 | -88,802,000 | 114,353,000 | 20,625,000 | 93,728,000 | -55,037,000 |
| Dec 2022 | 0 | -32,376,000 | -38,698,000 | 37,060,000 | 135,051,000 | -97,991,000 | -25,074,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1184.78 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| MRK | Merck & Co., Inc. | $366.84B | $148.69 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
News headlines (Yahoo Finance, 1h cache)
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
2026-09-28 12:35 · Yahoo
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
2026-09-23 09:30 · Yahoo
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
2026-08-31 13:55 · Yahoo
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
2026-08-24 08:00 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-08-14 20:05 · Yahoo
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
2026-08-14 13:55 · Yahoo
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
2026-08-10 08:45 · Yahoo
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
2026-08-10 07:30 · Yahoo
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
2026-08-07 02:35 · Yahoo
Oculis Reports Q2 2026 Financial Results and Provides Company Update
2026-08-06 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.